E5 and e6/e7 of high-risk HPVs cooperate to enhance cancer progression through EMT initiation

Cell Adhesion and Migration

Volumn 9, Issue 5, 2015, Pages 392-393

  Moustafa, Ala Eddin Al ^a,b,c,d  

^a QATAR UNIVERSITY   (Qatar)

^b MCGILL UNIVERSITY   (Canada)

^c Dept of Electrical and Computer Engineering   (Canada)

^d Syrian Research Cancer Center of the Syrian Society against Cancer   (Syrian Arab Republic)

Author keywords

Cancer progression; E5; E6 E7; Gene cooperation; High risk HPV

Indexed keywords

CAPSID PROTEIN; E4 PROTEIN; E5 ONCOPROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2B; FIBROBLAST GROWTH FACTOR RECEPTOR 2C; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; ONCOPROTEIN; PROTEIN E6; PROTEIN E7; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

CANCER GROWTH; CARCINOMA; CELL MOTILITY; CELLULAR IMMUNITY; DOUBLE-STRANDED DNA VIRUS; EARLY RESPONSE GENE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENITAL SYSTEM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; METASTASIS; NOTE; RNA SPLICING; TUMOR VIRUS; VIRUS INFECTION; VIRUS REPLICATION; WART VIRUS; ANIMAL; METABOLISM; NEOPLASM; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 84983162386     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.1080/19336918.2015.1042197     Document Type: Note

References (13)

1. Nguyen HP, Ramírez-Fort MK, Rady PL. The biology of human papillomaviruses. Curr Probl Dermatol 2014; 45:19-32. Epub 2014 Mar 13 http://dx.doi.org/10.1159/000355959
2. Tommasino M. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol 2014; 26:13-21 PMID:24316445 http://dx.doi.org/10.1016/j.semcancer.2013.11.002
3. Mighty KK, Laimins LA. The role of human papillomaviruses in oncogenesis. Recent Results Cancer Res 2014; 193:135-48 http://dx.doi.org/10.1007/978-3-642-38965-8_8
4. Al Moustafa AE, Al-Awadhi R, Missaoui N, Adam I, Durusoy R, Ghabreau L, Akil N, Ahmed HG, Yasmeen A, Alsbeih G. Human papillomavirusesrelated cancers. Presence and prevention strategies in the Middle east and north African regions. Hum Vaccin Immunother 2014; 10(7):1812-21 PMID:25424787 http://dx.doi.org/10.4161/hv.28742
5. Al Moustafa AE, Ghabreau L, Akil N, Rastam S, Alachkar A, Yasmeen A. High-risk HPVs and human carcinomas in the syrian population. Front Oncol 2014; 4:68 PMID:24765613 http://dx.doi.org/10.3389/fonc.2014.00068
6. Ranieri D, Belleudi F, Magenta A, Torrisi MR. HPV16 E5 expression induces switching from FGFR2b to FGFR2c and epithelial-mesenchymal transition. Int J Cancer. 2015 Jul 1; 137(1):61-72. http://dx.doi.org/10.1002/ijc.29373
7. Al Moustafa AE, Achkhar A, Yasmeen A. EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas. Front Biosci (Schol Ed) 2012; 4:671-84 PMID:22202084 http://dx.doi.org/10.2741/S292
8. Yasmeen A, Bismar TA, Kandouz M, Foulkes WD, Desprez PY, Al Moustafa AE. E6/E7 of HPV type 16 promotes cell invasion and metastasis of human breast cancer cells. Cell Cycle 2007; 6(16):2038-42 PMID:17721085 http://dx.doi.org/10.4161/cc.6.16.4555
9. Jung YS, Kato I, Kim HR. A novel function of HPV16- E6/E7 in epithelial-mesenchymal transition. Biochem Biophys Res Commun 2013; 435(3):339-44 PMID:23628416 http://dx.doi.org/10.1016/j.bbrc.2013.04.060
10. Shostak K, Zhang X, Hubert P, Göktuna SI, Jiang Z, Klevernic I, Hildebrand J, Roncarati P, Hennuy B, Ladang A, et al. NF-kB-induced KIAA1199 promotes survival through EGFR signalling. Nat Commun 2014; 5:5232 PMID:25366117 http://dx.doi.org/10.1038/ncomms6232
11. Kim SH, Juhnn YS, Kang S, Park SW, Sung MW, Bang YJ, Song YS. Human papillomavirus 16 E5 upregulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1,2 and PI3K/Akt. Cell Mol Life Sci 2006; 63(7-8):930-8 http://dx.doi.org/10.1007/s00018-005-5561-x
12. Kim KS, Park SA, Ko KN, Yi S, Cho YJ. Current status of human papillomavirus vaccines. Clin Exp Vaccine Res 2014; 3(2):168-75 PMID:25003090 http://dx.doi.org/10.7774/cevr.2014.3.2.168
13. Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch FX, de Sanjosé S. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012; 7(1):38 http://dx.doi.org/10.1186/1750-9378-7-38